High-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia

Recruiting N/A Interventional Study
Sarcopenia
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
75 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
846 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Sarcopenia is a progressive and generalised skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increased adverse outcomes including falls, functional decline, frailty, and mortality. In this project, the high-definition surface electromyography technology (HD-sEMG) signals will be analysed to extract features/ markers for the diagnosis of sa…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient aged 75 years and over * Score ≥4 on the SARC-F screening questionnaire * Enrolled in a social security plan (no AME) * Informed and consenting patient Exclusion Criteria: * BMI ≥30 kg/m2 * Severe psychiatric pathology or severe cognitive disorders that do not allow …
Contacts

Kiyoka KINUGAWA, Prof. MD PhD

+331 49 59 47 53

kiyoka.kinugawa@aphp.fr

CONTACT

Sofiane BOUDAOUD, Prof. PhD

+(33) 03 44 23 79 29

sofiane.boudaoud@utc.fr

CONTACT